The pair of Phase 2b clinical trials run by the HIV Vaccine Trials Network (HVTN) and the HIV Prevention Trials Network (HPTN) enrolled 4,625 participants at risk for HIV infection from communities in North and South America, Europe, and sub-Saharan Africa.
Diteko tse pedi tsa ditekeletso tsa kalafi tsa Karolo 2b tse di tsamaisiwang ke HIV Vaccine Trials Network (HVTN) le HIV Prevention Trials Network (HPTN) di kwadisise batsayakarolo ba le 4,625 ba ba mo kotsing ya go tshwaediwa ke HIV mo mafelong a Amerika Bokone le Borwa, Yuropa, le Aforika e e mo Borwa jwa Sahara.